Genmab — December 2019
-
Roches CD3xCD20 - Mosunetuzumab - bliver en
svær modstander grundet forspringet og at Roche er den værst tænkelige “modstander” Selv JW har udtrykt at han ikke ønskede sig den position. Genmab står både med Arzerra og CD3xCD20 frontalt imod Roche. Kun Genmab har sc versionerne så lad os håbe at patienterne foretrækker det ! -
Se selv hvad Genmab er op imod på CD3xCD20 https://twitter.com/filippo_bagnoli/status/1204147448370913280 evt søg på
Mosunetuzumab -
You know, we are all so convinced of Dara that we don't easily get impressed anymore, we sort of expect everyting will be great... But Dara really delivered again this ASH, much more as i thought before actually. If you look at all the expert comments, there is huge enthusiasm again
-
E L. I agree. I was blown away by all the amazing tweets about daratumab on Monday evening and night. They came from many of the leading experts in MM.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind